JP2020537649A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537649A5
JP2020537649A5 JP2020520804A JP2020520804A JP2020537649A5 JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5
Authority
JP
Japan
Prior art keywords
seq
sequence
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537649A (ja
JP7374891B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055733 external-priority patent/WO2019075417A1/en
Publication of JP2020537649A publication Critical patent/JP2020537649A/ja
Publication of JP2020537649A5 publication Critical patent/JP2020537649A5/ja
Priority to JP2023183034A priority Critical patent/JP2024012366A/ja
Application granted granted Critical
Publication of JP7374891B2 publication Critical patent/JP7374891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520804A 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法 Active JP7374891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183034A JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183034A Division JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Publications (3)

Publication Number Publication Date
JP2020537649A JP2020537649A (ja) 2020-12-24
JP2020537649A5 true JP2020537649A5 (https=) 2021-07-26
JP7374891B2 JP7374891B2 (ja) 2023-11-07

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520804A Active JP7374891B2 (ja) 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Country Status (36)

Country Link
US (3) US20190111150A1 (https=)
EP (2) EP3691692B8 (https=)
JP (2) JP7374891B2 (https=)
KR (4) KR102385495B1 (https=)
CN (1) CN111278467B (https=)
AR (1) AR115178A1 (https=)
AU (1) AU2018346969A1 (https=)
BR (1) BR112020007302B1 (https=)
CA (1) CA3077730A1 (https=)
CL (1) CL2020000977A1 (https=)
CO (1) CO2020005685A2 (https=)
CR (1) CR20200206A (https=)
CY (1) CY1123968T1 (https=)
DK (1) DK3691692T3 (https=)
DO (1) DOP2023000150A (https=)
EC (1) ECSP20025198A (https=)
ES (1) ES2864013T3 (https=)
HR (1) HRP20210436T8 (https=)
HU (1) HUE054037T2 (https=)
IL (1) IL273586A (https=)
LT (1) LT3691692T (https=)
MA (1) MA50752B1 (https=)
MD (1) MD3691692T2 (https=)
MX (1) MX2020003723A (https=)
PE (1) PE20210125A1 (https=)
PH (1) PH12020550417A1 (https=)
PL (1) PL3691692T3 (https=)
PT (1) PT3691692T (https=)
RS (1) RS61596B1 (https=)
RU (2) RU2771292C2 (https=)
SG (1) SG11202003378WA (https=)
SI (1) SI3691692T1 (https=)
SM (1) SMT202100184T1 (https=)
TW (2) TW202330039A (https=)
UY (1) UY37931A (https=)
WO (1) WO2019075417A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
RU2771292C2 (ru) * 2017-10-14 2022-04-29 Эббви Инк. Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
KR20220164773A (ko) * 2020-04-08 2022-12-13 앨리어다 테라퓨틱스, 인코포레이티드 혈액-뇌 장벽 전달용 조성물 및 방법
BR112022019841A2 (pt) * 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
WO2022020108A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
IL318625A (en) * 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
NZ599777A (en) * 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8765916B2 (en) * 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
EP3431504B1 (en) * 2012-01-31 2021-03-24 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
RU2771292C2 (ru) * 2017-10-14 2022-04-29 Эббви Инк. Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения

Similar Documents

Publication Publication Date Title
JP2020537649A5 (https=)
HRP20210436T1 (hr) Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe
JP2022064924A5 (https=)
JP2020500016A5 (https=)
JP2020506900A5 (https=)
JP2020524661A5 (https=)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20241563T1 (hr) Postupak liječenja ili ublažavanja metaboličkih poremećaja primjenom agonista glp-1 receptora konjugiranih na antagoniste želučanog inhibitornog peptidnog receptora (gipr)
JP2019504032A5 (https=)
EP4588940A3 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020500538A5 (https=)
JP2020519643A5 (https=)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
JP2015120706A5 (https=)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
PE20071055A1 (es) Anticuerpos anti mn
NZ603972A (en) Anti-fgfr2 antibodies
RU2010116152A (ru) Антитело против рецептора il-6
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2021533159A5 (https=)